Skip to main content
TipRanks
Go Ultimate75% OFF

Globe Life (TMJ) AI Stock Analysis

1 Followers
DE:TMJ

Globe Life

(XETRA:TMJ)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Premium GrowthBroad premium growth supports recurring revenue and demonstrates demand across both life and health products. The strong health trajectory and continued life expansion diversify growth drivers, while management’s 2027 outlook suggests the momentum is expected to persist beyond one reporting period.
Negative Factors
Margin PressureLower health margins and weaker trailing profitability indicate that revenue growth is not translating into earnings at the prior level of efficiency. If margin pressure persists, it could constrain earnings growth, reduce cash available for capital returns, and make future guidance more difficult to achieve.

Globe Life (TMJ) vs. iShares MSCI Germany ETF (EWG)

-10%0%10%20%30%40%50%DE:TMJ+23.53%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 11.44B
Dividend Yield
0.80%
Average Volume (3M)
16
Price to Earnings (P/E)
10.0
Beta (1Y)
0.19
Revenue Growth
0.35%
EPS Growth
4.25%
Country
Germany
Employees
3,695
Sector
Financial
Sector Strength
68
Industry
Insurance - Life

Globe Life Business Overview & Revenue Model

Company Description

Globe Life Inc. delivers diverse life insurance and supplementary health coverage, alongside annuity products, targeting households in the lower-middle to middle-income brackets throughout the United States. The company's operations are structured in...

Globe Life Earnings Call Summary

Earnings Call Date:Oct 21, 2026(Q3-2026)|% Change Since:-6.94%|Next Earnings Date:Feb 10, 2027
Earnings Call SentimentPositive

The call was broadly constructive. Management reported growth in operating income, total and health premiums, book value, sales activity, investment income, capital flexibility, and shareholder returns, while also outlining favorable claims experience, AI initiatives, Bermuda-related cash flow opportunities, and 2027 growth guidance. These positives were partially offset by a 2% decline in GAAP net income, lower 2026 EPS guidance, direct-to-consumer and American Income recruiting challenges, lower life and health margin metrics, CMS-related claims disruption, and significant volatility and losses at the early-stage Evri business.

Positive Updates

Operating Income and Book Value Growth
Third-quarter net operating income increased 1% year over year to $379 million, or $4.84 per share, compared with $4.81 per share a year ago. Book value per share increased 23% to $85.35 on a GAAP-reported basis and increased 11% to $103.62 excluding AOCI. Return on equity through September 30 was 19.7% on a GAAP-reported basis and 15.9% excluding AOCI.

Negative Updates

GAAP Net Income Decline
Third-quarter net income decreased 2% year over year to $361 million, or $4.62 per share, compared with $4.73 per share a year ago.

Company Guidance

For full year 2026, Globe Life expects total premium revenue growth to be around 6.5%, life premium revenue growth between 2.5% to 2.75%, life underwriting margin of 44% to 45% of premium, health premium revenue growth around 15%, health underwriting margin growth in the range of 4.0% to 4.5%, health underwriting margin of 22% to 24% of premium, administrative expenses at approximately 7.3% of premium, American Income average producing agent count down around 5%, Liberty National up around 9%, Family Heritage up around 5%, net life sales approximately flat at American Income, up around 10% at Liberty National and down around 9% at Direct to Consumer, and net health sales down around 7% at Liberty National, up approximately 10% at Family Heritage and up around 45% at United American; net operating earnings per diluted share are expected in the range of $15.35 to $15.65, normalized EPS growth approximately 8%, net investment income growth around 4.5%, required interest growth around 3.5%, excess investment income growth of 10% to 11%, average yield on total long term investments approximately 5.51%, and share repurchases in the range of $725 million to $775 million. For full year 2027, the company expects net operating earnings per diluted share in the range of $16.10 to $17.10, representing an increase of 7% at the midpoint, total premium revenue growth of 6% to 8%, life premium revenue growth of 4%, health premium revenue growth of 13% to 15%, life underwriting margin of 42% to 45% of premium, health underwriting margin of 20% to 24%, health underwriting margin dollar growth of 7% to 9%, net investment income growth in the range of 2.5% to 3.5%, required interest growth in the range of 3.5% to 4.0%, average yield on total long term investments between 5.50% to 5.55%, parent excess cash flows approximately $850 million to $950 million, and a cash conversion ratio in the range of 70% to 75% of net operating income; 2027 sales growth is expected to be mid- to high-single-digit at American Income, low double digit at Liberty National and low single digit at Direct to Consumer for net life sales, and low double digit at Liberty National and Family Heritage and high single digit at United American for net health sales.

Globe Life Risk Analysis

Globe Life disclosed 24 risk factors in its most recent earnings report. Globe Life reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Globe Life Peers Comparison

Overall Rating

UnderperformOutperform
Sector (68)

Financial Indicators

DE:TMJ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PRIPRI86Outperform$8.76B11.3130.97%1.67%7.93%16.30%
CNOCNO74Outperform$5.03B12.0416.62%1.30%2.47%53.14%
AFLAFL73Outperform$61.71B18.1811.85%1.96%-6.22%-10.65%
Sector *68Neutral$18.00B11.429.92%3.81%9.73%1.22%
SNFCASNFCA61Neutral$244.99M6.058.21%―-4.19%103.64%
UNMUNM51Neutral$11.94B53.832.23%2.54%-4.15%-72.51%

* Financial Sector Average

Performance Comparison

0%20%40%DE:TMJAFLCNOPRISNFCAUNMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:TMJ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:TMJGlobe Life Inc.140.9026.8423.53%
AFLAFLAC Incorporated124.3216.1614.94%
CNOCNO Financial Group53.9613.7534.21%
PRIPrimerica286.7633.0113.01%
SNFCASecurity National Financial9.011.2516.09%
UNMUnum Group75.901.992.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.